Registration is now open for MOEBIO Short Programs, a short training sessions created from the Design Health Barcelona Master under the framework of Moebio, the disruptive talent development initiative of Biocat.The sessions will take place at the Barcelona Science Park (PCB), covering the key issues in healthcare, innovation, management and entrepreneurship.
The Biocat Board of Trustees, presided over by Catalan Minister of Health Boi Ruiz, has appointed Dr. Albert Barberà the new CEO of the organization with headquarters at Parc Científic de Barcelona (PCB). Barberà, who until now has served as director of the Girona Biomedical Research Institute (IDIBGi), will take over in January for Dra. Montserrat Vendrell, who was CEO of Biocat from 2007 through September of this year when she took the reigns of the Barcelona Institute of Science and Technology (BIST), which is also located at PCB.
The Institute for Bioengineering of Catalonia (IBEC) at PCB is looking for PhD candidates to apply for the International PhD Programme at IBEC from ”la Caixa”– Severo Ochoa fellowships, and ‘Ayudas para contratos predoctorales para la formación de doctores 2016’ fellowships funded by Ministry of Economy and Competitiveness (Mineco). Students selected will have the opportunity to start your research career in a stimulating, interdisciplinary and high quality international scientific environment.
The Knowledge Transfer program in psoriasis between the academia and the industry developed by the Translational Immunology Group of the Department of Physiology and Immunology at the University of Barcelona (UB)- based at the Barcelona Science Park (PCB)– has been recognized with the Antoni Caparrós Award, one of the five awards that the UB Board of Trustees and the Bosch i Gimpera Foundation (FBG) granted this last Wednesday.
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods. This improved ability to foresee the possible adverse effects of drugs may entail saving many lives in the future. The study that is being conducted by researchers from IMIM (Hospital del Mar Medical Research Institute), Pompeu Fabra University (UPF), and the company Chemotargets at PCB, within the framework of the European eTOX project, was chosen for the cover of the journal Chemical Research in Toxicology.
Dr. Pau Bruguera and Dr. Andreu Veà have joined the scientific committee at GAEM Foundation (Multiple Sclerosis Affected Group). The scientific committee is composed of experts in various fields of biomedicine and entrepreneurship who advise and carry out the selection of research papers that may be a candidate to be included in the Accelerator Program.
The start-up Artax Biopharma –focusing on the development of first-in-class drugs to treat autoimmune diseases- has closed a Series B series investment funding round totaling $10 Million to boost clinical trials of its most advanced compound, drug AX- 024. This biotech- based in Cambridge (Massachusetts) and founded by Damià Tormo, a scientist and entrepreneur from Valencia– leads a team in Spain that manages a large part of the project in Europe from its offices located in Valencia and at Barcelona Science Park (PCB).
Protein NBS1, which plays a key role in DNA damage repair, is required for macrophage functional activity. This is one of the conclusions of a scientific paper published in the journal Blood—considered one of the best scientific publications in the field of haematology— and signed by a team of experts from the Faculty of Biology of the University of Barcelona (UB), Consolidated Research Group Macrophage Biology –located at the Barcelona Science Park (PCB)– and the Institute for Research in Biomedicine (IRB Barcelona). The protein also has implications for understanding the immune defects observed in patients with Nijmegen breakage syndrome and other related disorders.
Jordi Quintana, head of the Drug Discovery Plaform at the Barcelona Science Park (PCB), has been appointed member of the Executive Board of the Data Mining and Repurposing Task Force of the International Rare Diseases Research Consortium (IRDiRC). Spain was the first European country to join the consortium promoted in 2011 by the European Commission and the National Institute of Health of the US aimed at fostering international cooperation in the research of more than 7000 rare diseases recorded to date.
A European consortium led by Centre Tecnològic Leitat –through its Biomed Division, located at the Barcelona Science Park (PCB)– has started the Glass-Laser Multiplexed Biosensor (GLAM) project, the aim of which is to develop a photonic-based point-of-care device for a non-invasive diagnosis of Genitourinary Cancer (GU). The GLAM project which will expand for 4 years will involve the participation of 10 European organizations with resources and capabilities from the academia and scientific and business field, among them the Institute for Bioengineering of Catalonia (IBEC), located at PCB.
